ABSTRACT
The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) play an essential role in the receptor signaling of cytokines that have been implicated in the pathogenesis of severe asthma, and there is emerging interest in the development of small-molecule-inhaled JAK inhibitors as treatments. Here, we describe the optimization of a quinazoline series of JAK inhibitors and the results of mouse lung pharmacokinetic (PK) studies where only low concentrations of parent compound were observed. Subsequent investigations revealed that the low exposure was due to metabolism by aldehyde oxidase (AO), so we sought to identify quinazolines that were not metabolized by AO. We found that specific substituents at the quinazoline 2-position prevented AO metabolism and this was rationalized through computational docking studies in the AO binding site, but they compromised kinome selectivity. Results presented here highlight that AO metabolism is a potential issue in the lung.
Subject(s)
Aldehyde Oxidase/metabolism , Janus Kinase Inhibitors/pharmacokinetics , Lung/metabolism , Administration, Intranasal , Administration, Intravenous , Animals , Binding Sites , Drug Delivery Systems , Female , Humans , Janus Kinase Inhibitors/administration & dosage , Janus Kinase Inhibitors/chemical synthesis , Liver/metabolism , Mice , Mice, Inbred BALB C , Models, Molecular , Molecular Docking Simulation , Quinazolines/chemical synthesis , Quinazolines/pharmacokinetics , Quinazolines/pharmacology , Structure-Activity RelationshipABSTRACT
Herein, a series of 2,3-dihydrobenzofurans have been developed as highly potent bromo and extra-terminal domain (BET) inhibitors with 1000-fold selectivity for the second bromodomain (BD2) over the first bromodomain (BD1). Investment in the development of two orthogonal synthetic routes delivered inhibitors that were potent and selective but had raised in vitro clearance and suboptimal solubility. Insertion of a quaternary center into the 2,3-dihydrobenzofuran core blocked a key site of metabolism and improved the solubility. This led to the development of inhibitor 71 (GSK852): a potent, 1000-fold-selective, highly soluble compound with good in vivo rat and dog pharmacokinetics.
Subject(s)
Benzofurans/pharmacology , Proteins/antagonists & inhibitors , Benzofurans/chemical synthesis , Benzofurans/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Proteins/metabolism , Solubility , Structure-Activity RelationshipABSTRACT
Domain-specific BET bromodomain ligands represent an attractive target for drug discovery with the potential to unlock the therapeutic benefits of antagonizing these proteins without eliciting the toxicological aspects seen with pan-BET inhibitors. While we have reported several distinct classes of BD2 selective compounds, namely, GSK620, GSK549, and GSK046, only GSK046 shows high aqueous solubility. Herein, we describe the lead optimization of a further class of highly soluble compounds based upon a picolinamide chemotype. Focusing on achieving >1000-fold selectivity for BD2 over BD1 ,while retaining favorable physical chemical properties, compound 36 was identified as being 2000-fold selective for BD2 over BD1 (Brd4 data) with >1 mg/mL solubility in FaSSIF media. 36 represents a valuable new in vivo ready molecule for the exploration of the BD2 phenotype.
Subject(s)
Cell Cycle Proteins/antagonists & inhibitors , Pyridines/pharmacology , Transcription Factors/antagonists & inhibitors , Cell Cycle Proteins/metabolism , Dose-Response Relationship, Drug , Humans , Models, Molecular , Molecular Structure , Pyridines/chemistry , Structure-Activity Relationship , Transcription Factors/metabolismABSTRACT
The profound efficacy of pan-BET inhibitors is well documented, but these epigenetic agents have shown pharmacology-driven toxicity in oncology clinical trials. The opportunity to identify inhibitors with an improved safety profile by selective targeting of a subset of the eight bromodomains of the BET family has triggered extensive medicinal chemistry efforts. In this article, we disclose the identification of potent and selective drug-like pan-BD2 inhibitors such as pyrazole 23 (GSK809) and furan 24 (GSK743) that were derived from the pyrrole fragment 6. We transpose the key learnings from a previous pyridone series (GSK620 2 as a representative example) to this novel class of inhibitors, which are characterized by significantly improved solubility relative to our previous research.
Subject(s)
Furans/pharmacology , Proteins/antagonists & inhibitors , Pyrazoles/pharmacology , Dose-Response Relationship, Drug , Furans/chemistry , Humans , Molecular Structure , Proteins/metabolism , Pyrazoles/chemistry , Structure-Activity RelationshipABSTRACT
A number of reports have recently been published describing the discovery and optimization of bromo and extraterminal inhibitors which are selective for the second bromodomain (BD2); these include our own work toward GSK046 (3) and GSK620 (5). This paper describes our approach to mitigating the genotoxicity risk of GSK046 by replacement of the acetamide functionality with a heterocyclic ring. This was followed by a template-hopping and hybridization approach, guided by structure-based drug design, to incorporate learnings from other BD2-selective series, optimize the vector for the amide region, and explore the ZA cleft, leading to the identification of potent, selective, and bioavailable compounds 28 (GSK452), 39 (GSK737), and 36 (GSK217).
Subject(s)
Cell Cycle Proteins/antagonists & inhibitors , Protein Domains/drug effects , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Transcription Factors/antagonists & inhibitors , Cell Cycle Proteins/chemistry , Cell Cycle Proteins/metabolism , Drug Design , Drug Discovery , Humans , Transcription Factors/chemistry , Transcription Factors/metabolismABSTRACT
The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains. To date, small molecule inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biological effects. To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required. In this regard, we report the discovery of a potent probe molecule possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs. Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chemical functionality appended to the previously developed I-BET151 scaffold. Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.
Subject(s)
Anti-Inflammatory Agents/chemistry , Cell Cycle Proteins/antagonists & inhibitors , Drug Design , Transcription Factors/antagonists & inhibitors , Animals , Anti-Inflammatory Agents/metabolism , Anti-Inflammatory Agents/pharmacology , Binding Sites , Cell Cycle Proteins/classification , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cytokines/metabolism , Half-Life , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Male , Mice , Molecular Dynamics Simulation , Phylogeny , Protein Domains , Quinolones/chemistry , Quinolones/metabolism , Quinolones/pharmacology , Transcription Factors/classification , Transcription Factors/metabolismABSTRACT
Pan-BET inhibitors have shown profound efficacy in a number of in vivo preclinical models and have entered the clinic in oncology trials where adverse events have been reported. These inhibitors interact equipotently with the eight bromodomains of the BET family of proteins. To better understand the contribution of each domain to their efficacy and to improve from their safety profile, selective inhibitors are required. This Letter discloses the profile of GSK973, a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive preclinical in vitro and in vivo characterization.
ABSTRACT
Pan-bromodomain and extra terminal domain (BET) inhibitors interact equipotently with the eight bromodomains of the BET family of proteins and have shown profound efficacy in a number of in vitro phenotypic assays and in vivo pre-clinical models in inflammation or oncology. A number of these inhibitors have progressed to the clinic where pharmacology-driven adverse events have been reported. To better understand the contribution of each domain to their efficacy and improve their safety profile, selective inhibitors are required. This article discloses the profile of GSK046, also known as iBET-BD2, a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive pre-clinical in vitro and in vivo characterization.
Subject(s)
Amides/chemical synthesis , Drug Design , Transcription Factors/antagonists & inhibitors , Amides/chemistry , Amides/metabolism , Animals , Benzene Derivatives/chemistry , Binding Sites , Cell Cycle Proteins/antagonists & inhibitors , Cell Cycle Proteins/metabolism , Crystallography, X-Ray , Humans , Microsomes, Liver/metabolism , Molecular Dynamics Simulation , Protein Domains , Quantum Theory , Rats , Structure-Activity Relationship , Transcription Factors/metabolismABSTRACT
The profound efficacy, yet associated toxicity of pan-BET inhibitors is well documented. The possibility of an ameliorated safety profile driven by significantly selective (>100-fold) inhibition of a subset of the eight bromodomains is enticing, but challenging given the close homology. Herein, we describe the X-ray crystal structure-directed optimization of a novel weak fragment ligand with a pan-second bromodomain (BD2) bias, to potent and highly BD2 selective inhibitors. A template hopping approach, enabled by our parallel research into an orthogonal template (15, GSK046), was the basis for the high selectivity observed. This culminated in two tool molecules, 20 (GSK620) and 56 (GSK549), which showed an anti-inflammatory phenotype in human whole blood, confirming their cellular target engagement. Excellent broad selectivity, developability, and in vivo oral pharmacokinetics characterize these tools, which we hope will be of broad utility to the field of epigenetics research.
Subject(s)
Anti-Inflammatory Agents/chemistry , Ligands , Transcription Factors/antagonists & inhibitors , Administration, Oral , Amides/chemistry , Amides/metabolism , Amides/pharmacokinetics , Animals , Anti-Inflammatory Agents/metabolism , Anti-Inflammatory Agents/pharmacokinetics , Binding Sites , Cell Cycle Proteins/antagonists & inhibitors , Cell Cycle Proteins/metabolism , Crystallography, X-Ray , Dogs , Half-Life , Humans , Hydrogen Bonding , Male , Molecular Dynamics Simulation , Protein Domains , Rats , Rats, Wistar , Structure-Activity Relationship , Transcription Factors/metabolismABSTRACT
Over the last decade, a number of computational methods have been developed, which attempt to evaluate the thermodynamic properties of individual water molecules at the solute-solvent interface, in order to assess contributions to protein-ligand binding. In some cases, these tools tell us what we already know, e.g. that hydrophobic pockets prefer lipophilic substituents, and in other cases the methods only seem to add clarity when retrospectively applied. Hence we have grappled with how to utilize such approaches to understand non-intuitive results and to generate chemistry ideas that otherwise would not have been developed. Here we provide our perspective on these methods and describe how results have been interpreted and applied. We include examples from GSK and elsewhere that highlight how water methods have been (1) utilized retrospectively to explain non-intuitive structure- activity relationships and (2) applied prospectively for chemistry design. Finally, we discuss where this field of study could lead to maximal impact in drug discovery research.
Subject(s)
Drug Design , Water/chemistry , Ligands , Molecular Structure , Proteins/chemistry , ThermodynamicsABSTRACT
The ubiquitously expressed glucocorticoid receptor (GR) is a major drug target for inflammatory disease, but issues of specificity and target tissue sensitivity remain. We now identify high potency, non-steroidal GR ligands, GSK47867A and GSK47869A, which induce a novel conformation of the GR ligand-binding domain (LBD) and augment the efficacy of cellular action. Despite their high potency, GSK47867A and GSK47869A both induce surprisingly slow GR nuclear translocation, followed by prolonged nuclear GR retention, and transcriptional activity following washout. We reveal that GSK47867A and GSK47869A specifically alter the GR LBD structure at the HSP90-binding site. The alteration in the HSP90-binding site was accompanied by resistance to HSP90 antagonism, with persisting transactivation seen after geldanamycin treatment. Taken together, our studies reveal a new mechanism governing GR intracellular trafficking regulated by ligand binding that relies on a specific surface charge patch within the LBD. This conformational change permits extended GR action, probably because of altered GR-HSP90 interaction. This chemical series may offer anti-inflammatory drugs with prolonged duration of action due to altered pharmacodynamics rather than altered pharmacokinetics.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Benzamides/pharmacology , HSP90 Heat-Shock Proteins/metabolism , Indazoles/pharmacology , Receptors, Glucocorticoid/metabolism , Androstadienes/chemistry , Androstadienes/pharmacology , Anti-Inflammatory Agents/chemistry , Benzamides/chemistry , Benzoquinones/pharmacology , Dexamethasone/chemistry , Dexamethasone/pharmacology , Fluticasone , HeLa Cells , Humans , Immune System Diseases , Indazoles/chemistry , Lactams, Macrocyclic/pharmacology , Ligands , Molecular Targeted Therapy , Protein Conformation , Protein Interaction Domains and Motifs/genetics , Protein Transport , Receptors, Glucocorticoid/agonists , Transcriptional Activation/drug effectsABSTRACT
Inhibition of Itk potentially constitutes a novel, nonsteroidal treatment for asthma and other T-cell mediated diseases. In-house kinase cross-screening resulted in the identification of an aminopyrazole-based series of Itk inhibitors. Initial work on this series highlighted selectivity issues with several other kinases, particularly AurA and AurB. A template-hopping strategy was used to identify a series of aminobenzothiazole Itk inhibitors, which utilized an inherently more selective hinge binding motif. Crystallography and modeling were used to rationalize the observed selectivity. Initial exploration of the SAR around this series identified potent Itk inhibitors in both enzyme and cellular assays.
ABSTRACT
Bromodomain-containing proteins are key epigenetic regulators of gene transcription and readers of the histone code. However, the therapeutic benefits of modulating this target class are largely unexplored due to the lack of suitable chemical probes. This article describes the generation of lead molecules for the BET bromodomains through screening a fragment set chosen using structural insights and computational approaches. Analysis of 40 BRD2/fragment X-ray complexes highlights both shared and disparate interaction features that may be exploited for affinity and selectivity. Six representative crystal structures are then exemplified in detail. Two of the fragments are completely new bromodomain chemotypes, and three have never before been crystallized in a bromodomain, so our results significantly extend the limited public knowledge-base of crystallographic small molecule/bromodomain interactions. Certain fragments (including paracetamol) bind in a consistent mode to different bromodomains such as CREBBP, suggesting their potential to act as generic bromodomain templates. An important implication is that the bromodomains are not only a phylogenetic family but also a system in which chemical and structural knowledge of one bromodomain gives insights transferrable to others.
Subject(s)
Models, Molecular , Peptidomimetics/chemistry , Protein Serine-Threonine Kinases/antagonists & inhibitors , Acetaminophen/chemistry , Amino Acid Sequence , Cell Cycle Proteins , Crystallography, X-Ray , Fluorescence Polarization , Humans , Indolizines/chemistry , Molecular Sequence Data , Molecular Structure , Nuclear Proteins/antagonists & inhibitors , Nuclear Proteins/chemistry , Protein Binding , Protein Serine-Threonine Kinases/chemistry , Protein Structure, Tertiary , Pyridines/chemistry , Pyrrolidinones/chemistry , Quantitative Structure-Activity Relationship , Quinazolinones/chemistry , RNA-Binding Proteins/antagonists & inhibitors , RNA-Binding Proteins/chemistry , Transcription Factors/antagonists & inhibitors , Transcription Factors/chemistryABSTRACT
Heteroalicyclic carboxamidines were synthesised and evaluated as inhibitors of nitric oxide synthases. (2R)-2-Pyrrolidinecarboxamidine, in particular, was shown to be a highly potent in vitro (IC(50)=0.12 µM) and selective iNOS inhibitor (>100-fold vs both eNOS and nNOS), with probable binding to the key anchoring glutamate residue and co-ordination to the haem iron.
Subject(s)
Amidines/chemical synthesis , Amidines/pharmacology , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Heme/antagonists & inhibitors , Heterocyclic Compounds/chemical synthesis , Nitric Oxide Synthase Type II/antagonists & inhibitors , Proline/analogs & derivatives , Amidines/chemistry , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Humans , Inhibitory Concentration 50 , Models, Molecular , Molecular Structure , Proline/chemical synthesis , Proline/chemistry , Proline/pharmacologyABSTRACT
Aryl aminopyrazole amides capped with N-alkylbenzamides 13-16 are selective glucocorticoid receptor agonists. 2,6-Disubstituted benzamides have prednisolone-like potency or better in vitro. Good oral exposure was demonstrated in the rat, with compounds with lower lipophilicity, for example N-hydroxyethyl benzamides (e.g., 16e).
Subject(s)
Benzamides/chemical synthesis , Pyrazoles/chemical synthesis , Receptors, Glucocorticoid/agonists , Administration, Oral , Animals , Benzamides/pharmacology , Humans , Hydrophobic and Hydrophilic Interactions , Prednisolone , Pyrazoles/pharmacology , Rats , Structure-Activity RelationshipABSTRACT
A series of diaryl ether substituted 4-pyridones have been identified as having potent antimalarial activity superior to that of chloroquine against Plasmodium falciparum in vitro and murine Plasmodium yoelii in vivo. These were derived from the anticoccidial drug clopidol through a systematic study of the effects of varying the side chain on activity. Relative to clopidol the most active compounds show >500-fold improvement in IC50 for inhibition of P. falciparum in vitro and about 100-fold improvement with respect to ED50 against P. yoelii in mice. These compounds have been shown elsewhere to act selectively by inhibition of mitochondrial electron transport at the cytochrome bc1 complex.
Subject(s)
Antimalarials/chemical synthesis , Malaria/drug therapy , Plasmodium falciparum/drug effects , Plasmodium yoelii , Pyridones/chemical synthesis , Animals , Antimalarials/chemistry , Antimalarials/pharmacology , Mice , Parasitic Sensitivity Tests , Pyridones/chemistry , Pyridones/pharmacology , Structure-Activity RelationshipABSTRACT
Docking is a computational technique that samples conformations of small molecules in protein binding sites; scoring functions are used to assess which of these conformations best complements the protein binding site. An evaluation of 10 docking programs and 37 scoring functions was conducted against eight proteins of seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization. All of the docking programs were able to generate ligand conformations similar to crystallographically determined protein/ligand complex structures for at least one of the targets. However, scoring functions were less successful at distinguishing the crystallographic conformation from the set of docked poses. Docking programs identified active compounds from a pharmaceutically relevant pool of decoy compounds; however, no single program performed well for all of the targets. For prediction of compound affinity, none of the docking programs or scoring functions made a useful prediction of ligand binding affinity.
Subject(s)
Ligands , Proteins/chemistry , Quantitative Structure-Activity Relationship , Algorithms , Binding Sites , Drug Design , Models, Molecular , Molecular Conformation , Protein Binding , SoftwareABSTRACT
Inhibitors of transforming growth factor beta (TGF-beta) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.
Subject(s)
Activin Receptors, Type I/antagonists & inhibitors , Benzamides/chemical synthesis , Pyrazoles/chemical synthesis , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Acute Disease , Administration, Oral , Animals , Benzamides/pharmacokinetics , Benzamides/pharmacology , Collagen Type I/antagonists & inhibitors , Collagen Type I/biosynthesis , Collagen Type I/genetics , Collagen Type I, alpha 1 Chain , Dimethylnitrosamine , Fibrosis , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Liver Cirrhosis/chemically induced , Liver Cirrhosis/metabolism , Male , Models, Molecular , Protein Serine-Threonine Kinases , Puromycin Aminonucleoside , Pyrazoles/pharmacokinetics , Pyrazoles/pharmacology , RNA, Messenger/antagonists & inhibitors , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Receptor, Transforming Growth Factor-beta Type I , Structure-Activity RelationshipABSTRACT
Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-beta type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 = 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited selectivity over p38 mitogen-activated protein kinase. The X-ray crystal structure of 19 in complex with human ALK5 is described, confirming the binding mode proposed from docking studies.
Subject(s)
Activin Receptors, Type I/antagonists & inhibitors , Naphthyridines/chemical synthesis , Naphthyridines/pharmacology , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Binding Sites , Crystallography, X-Ray , Humans , Inhibitory Concentration 50 , Phosphorylation/drug effects , Protein Binding , Protein Serine-Threonine Kinases , Pyrazoles/chemical synthesis , Pyrazoles/pharmacology , Receptor, Transforming Growth Factor-beta Type I , Structure-Activity RelationshipABSTRACT
A series of chiral, (S)-proline-alpha-methylpyrrolidine-5,5-trans-lactam serine protease inhibitors has been developed as antivirals of human cytomegalovirus (HCMV). The SAR of the functionality on the proline nitrogen has shown that derivatives of para-substituted phenyl ureas > para-substituted phenyl sulfonamides > para-substituted phenyl carboxamide for activity against HCMV deltaAla protease, producing para-substituted phenyl ureas with single figure nM potency (K(i)) against the viral enzyme. The SAR of the functionality on the lactam nitrogen has defined the steric and electronic requirements for high human plasma stability while retaining good activity against HCMV protease. The combination of high potency against HCMV deltaAla protease and high human plasma stability has produced compounds with significant in vitro antiviral activity against human cytomegalovirus with the 6-hydroxymethyl benzothiazole derivative 72 being equivalent in potency to ganciclovir. The parent benzothiazole 56 had good pharmacokinetics in dogs with 29% bioavailability and good brain and ocular penetration in guinea pigs.